I don’t agree in a buy-out. You give up so much
I don’t agree in a buy-out. You give up so much potential. We as investors don’t need the help and we will cross that finish line. For me... that is happening as we speak behind the scenes as we don’t know what is happening and Cytodyn can’t divulge everything if the government is somehow involved behind the scenes with an approval. Myself I believe they are aware of where we are. Take the Medicare and Medicaid billing numbers by name written in for Cytodyn. This is only a little smoke but has some creative thinking possibly going on that we don’t know about.
At this point we don’t need a buy out to further our process. We are on the cusp of greatness and it would only reduce our investment to share the potential with another pharmaceutical company by selling out. I am not a proponent of a fast nickel when a slow dime is just around the corner. I don’t believe it’s going to be a slow dime either is going to be a wind fall of dimes... giving up a potential of something amazing like Vyrologix is like giving up an early stock like Microsoft or Apple and taking a few thousand dollars for what could be millions of dollars.
To me... I look at inflammation as the single worst symptom of most diseases and what does Leronlimab do? Reduce inflammation. How does this happen? It stops the inflammation by stopping the immune response. So we have an amazing drug that regulates the immune system and stops the immune system from attacking the victim and does this all with unmatched safety. When you look at the action of this little molecule. You have to see that this method of action could very well work for many diseases. Stopping them cold in their tracks. With all this potential I will wait for the best return an investor can hope for. The new Amazon type investment is Cytodyn. 3-5 years from now... we will all be laughing at the thought of what if... what if we would of sold out or been bought out. When we are traveling the world with all the money from our Vyrologix investment that helped Vyrologix help to make the world become a Safe place again. Especially if we become a vaccine booster to lengthen the time of vaccine that might only be good for 6 months or so. Covid could be huge for us if that happen. But even if it doesn’t. There are many ways looking forward that you can see this drug being a blockbuster for not just one indication. But for many blockbuster indications. Call me greedy... I don’t want to share that with other big pharmaceutical companies when we don’t have to. We are on the cusp of something great. But that’s just my opinion. You others can have your opinions. It wouldn’t take away from my beliefs and I will hold Vyrologix for that 3-5 years and still keep a large share invested forever.
11
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...
Continue Reading
Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...
Continue Reading
The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...
Continue Reading
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...
Continue Reading
BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...
Continue Reading
Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...
Continue Reading
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
Top 5 Most Recently Viewed Articles
The 20th Anniversary of the Driskell Prize Gala The David C. Driskell Prize Gala, often referred to as the "Met Gala of the South," is an extraordinary annual event that grandly honors the recipient of the Driskell Prize in African American Art and Art History. This prize holds the distinguished title of being the first national award recognizing the invaluable...
Continue Reading
Smartsheet Strengthens Leadership with New Vice President Smartsheet, a leader in enterprise-grade work management, has made a significant decision in appointing Eva Schoenleitner as their Vice President of Partner. This move highlights the company’s focus on reinforcing their partner ecosystem and driving further growth in the tech industry. Experience That Counts...
Continue Reading
Piedmont Heart Institute Sets New Transplant Record Piedmont Heart Institute recently demonstrated its commitment to advancing cardiac care by achieving a remarkable milestone. In the year 2024, the institute performed 103 heart transplants at Piedmont Atlanta Hospital, establishing a new organizational record. This significant accomplishment underscores the institute's...
Continue Reading
Arizona Metals Corp Unveils New Mineral Resource Estimate Arizona Metals Corp (TSX: AMC, OTC: AZMCF) has made waves in the mining sector with the recent announcement of its inaugural Mineral Resource Estimate (MRE) for the Kay Mine Project. This project signifies a significant milestone for the company, highlighting its resources and potential for growth. Insights into...
Continue Reading
Leidos Holdings, Inc. Announces Increased Dividend Leidos Holdings, Inc. (NYSE: LDOS) has made an exciting announcement regarding its quarterly cash dividend. The company’s board of directors has confirmed a quarterly cash dividend of $0.43 for each outstanding share of its common stock. This marks an increase of $0.03 from the previous dividend of $0.40 per share,...
Continue Reading